Please login to the form below

Not currently logged in
Email:
Password:

Investigation into Merck & Co drug

The US Food and Drugs Administration announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The US Food and Drugs Administration (FDA) announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The FDA has said that is investigation a possible association between the use of the drug and suicidal behaviour and thinking after analysing the most up-to-date information pertaining to the use of Singulair.

Singulair is a leukotriene receptor antagonist indicated for the treatment of patients with asthma and symptoms of allergic rhinitis and to prevent exercise-induced asthma.

The FDA said: "Until further information is available, healthcare professionals and caregivers should monitor patients taking Singulair for suicidality (suicidal thinking and behaviour) and changes in behaviour and mood."

The FDA did, however, caution that "patients should not stop taking Singulair before talking to their doctor if they have questions about this new information."

Evaluation of the date and the possible link between Singulair and suicidal behaviour and thinking may take up to nine months at which point the FDA's findings will be made available to the public.

27th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics